1.Hope for Cirrhosis Patients with Genotype 1 Hepatitis C Virus Who Failed the Previous Treatment.
The Korean Journal of Gastroenterology 2015;66(2):131-133
No abstract available.
Antiviral Agents/*therapeutic use
;
Benzimidazoles/*therapeutic use
;
Female
;
Fluorenes/*therapeutic use
;
Hepacivirus/*classification
;
Hepatitis C, Chronic/*drug therapy
;
Humans
;
Liver Cirrhosis/*drug therapy
;
Male
;
Ribavirin/*therapeutic use
;
Uridine Monophosphate/*analogs & derivatives
2.Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand.
Srivicha KRUDSOOD ; Noppadon TANGPUKDEE ; Sant MUANGNOICHAROEN ; Vipa THANACHARTWET ; Nutthanej LUPLERTLOP ; Siripan SRIVILAIRIT ; Polrat WILAIRATANA ; Shigeyuki KANO ; Pascal RINGWALD ; Sornchai LOOAREESUWAN
The Korean Journal of Parasitology 2007;45(2):111-114
Chloroquine remains the drug of choice for the treatment of vivax malaria in Thailand. Mixed infections of falciparum and vivax malaria are also common in South-East Asia. Laboratory confirmation of malaria species is not generally available. This study aimed to find alternative regimens for treating both malaria species by using falciparum antimalarial drugs. From June 2004 to May 2005, 98 patients with Plasmodium vivax were randomly treated with either artemether-lumefantrine (n = 47) or chloroquine (n = 51). Both treatments were followed by 15 mg of primaquine over 14 days. Adverse events and clinical and parasitological outcomes were recorded and revealed similar in both groups. The cure rate was 97.4% for the artemether-lumefantrine treated group and 100% for the chloroquine treated group. We concluded that the combination of artemether-lumefantrine and primaquine was well tolerated, as effective as chloroquine and primaquine, and can be an alternative regimen for treatment of vivax malaria especially in the event that a mixed infection of falciparum and vivax malaria could not be ruled out.
Adolescent
;
Aged
;
Animals
;
Antimalarials/adverse effects/*therapeutic use
;
Artemisinins/adverse effects/*therapeutic use
;
Chloroquine/adverse effects/*therapeutic use
;
Drug Therapy, Combination
;
Ethanolamines/adverse effects/*therapeutic use
;
Female
;
Fluorenes/adverse effects/*therapeutic use
;
Humans
;
Malaria, Vivax/*drug therapy
;
Male
;
Middle Aged
;
Parasitemia
;
Plasmodium vivax/drug effects
;
Primaquine/therapeutic use
;
Thailand
;
Treatment Outcome
3.Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naïve Patients Infected with Genotype 1b Hepatitis C Virus.
Ye WANG ; Hui-Ying RAO ; Xing-Wang XIE ; Lai WEI
Chinese Medical Journal 2015;128(19):2625-2631
BACKGROUNDIt has been reported that several baseline polymorphisms of direct-acting antivirals (DAAs) agents resistance-associated variants (RAVs) would affect the treatment outcomes of patients chronically infected with hepatitis C virus (CHC). The aim of this study is to investigate the prevalence of DAAs RAVs in treatment-naÏve GT1b CHC patients.
METHODSDirect sequencing and ultra-deep sequencing of the HCV NS3, NS5A, and NS5B gene were performed in baseline serum samples of treatment-naÏve patients infected with genotype 1b hepatitis C virus (HCVs).
RESULTSOne hundred and sixty CHC patients were studied. Complete sequence information was obtained for 145 patients (NS3), 148 patients (NS5A), and 137 patients (NS5B). Treatment-failure associated variants of DAAs were detected: 56.6% (82/145) of the patients presented S122G for simeprevir (NS3 protease inhibitor); 10.1% (14/148) of the patients presented Y93H for daclatasvir and ledipasvir (NS5A protein inhibitors); 94.2% (129/137) of the patients presented C316N for sofosbuvir (NS5B polymerase inhibitor). Nearly, all of the DAAs RAVs detected by ultra-deep sequencing could be detected by direct sequencing.
CONCLUSIONSThe majority of genotype 1b CHC patients in China present a virus population carrying HCV DAAs RAVs. Pretreatment sequencing of HCV genome might need to be performed when patients infected with GT1b HCV receiving DAAs-containing regimens in China. Population sequencing would be quite quantified for the work.
Adult ; Aged ; Antiviral Agents ; therapeutic use ; Benzimidazoles ; therapeutic use ; China ; Drug Resistance, Viral ; genetics ; Female ; Fluorenes ; therapeutic use ; Genotype ; Hepacivirus ; drug effects ; pathogenicity ; Hepatitis C ; drug therapy ; High-Throughput Nucleotide Sequencing ; Humans ; Imidazoles ; therapeutic use ; Male ; Middle Aged ; Polymorphism, Genetic ; genetics ; Simeprevir ; therapeutic use